AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00415974 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health promotion materials on physical activity and nutrition
Description: PACE-PC adolescents and their families will receive information regarding healthy eating and physical activity behaviors on a weekly basis via mail. These behavioral-based materials will educate participants and their families on healthy behaviors that are necessary for successful weight management. Topics will coincide with the intervention goals and include supplemental information to enhance quality of life and improve body image. Topics will include realistic goal-setting and attainment, how to handle holidays and celebrations, eating fast food, grocery shopping and food preparation, and relapse prevention, etc.. Topics will include specific strategies related to the adolescent's readiness to change to reflect processes that are most appropriate. Content from these materials will be addressed by the phone counselors to ensure that participants received and understood intervention messages.
Study NCT01585792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01350986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Self-help Workbook + Counseling Telephone Calls
Description: In intervention period of 5 months parents work through 8 cognitive-behavioral self-help booklets (FLOH) and additionally receive 10 counseling telephone calls. Primary purpose of telephone calls is to clarify content of the booklets and support parents in managing their homework assignments accompanied with each booklet. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on the therapy manual Treatment program for children with hyperactive and oppositional problem behavior (THOP) (Döpfner, Schürmann, \& Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, \& Lehmkuhl, 2006).
Study NCT01350986 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Directive Self-Help Workbook + Counseling Telephone Calls
Description: In intervention period of 5 months parents are provided 8 non-directive self-help booklets and additionally receive 10 non-directive counseling telephone calls. If the telephone calls are used to clarify content of the booklets or to discuss other child and parenting related topics is at the parents' discretion. Main focus for counselor is to be congruent, empathic and to have unconditional positive regard toward the parents. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on Parent effectiveness training (Gordon, 1970) and Teaching children self-discipline at home and at school (Gordon, 1989).
Study NCT03915600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quinoa
Description: Personalized diet added with quinoa
Study NCT03915600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: personalized diet added with flaxseed
Study NCT00415974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promotion materials on physical activity and nutrition
Description: PACE-PC adolescents and their families will receive information regarding healthy eating and physical activity behaviors on a weekly basis via mail. These behavioral-based materials will educate participants and their families on healthy behaviors that are necessary for successful weight management. Topics will coincide with the intervention goals and include supplemental information to enhance quality of life and improve body image. Topics will include realistic goal-setting and attainment, how to handle holidays and celebrations, eating fast food, grocery shopping and food preparation, and relapse prevention, etc.. Topics will include specific strategies related to the adolescent's readiness to change to reflect processes that are most appropriate. Content from these materials will be addressed by the phone counselors to ensure that participants received and understood intervention messages.
Study NCT01836458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: Patients will receive KAE609 single dose at a different dose level in each cohort.
Study NCT03066375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiography-Doppler
Description: Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
Study NCT02698436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acne Mask
Description: The light therapy device contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes
Study NCT02698436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5% Benzoyl Peroxide Treatment
Description: The BPO treatment is applied twice daily, once in the morning and once in the evening
Study NCT03740074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAI
Description: Consenting subjects will be given a Mio Slice, along with instructions on how to utilize the device.~They will register on line with PAI Health, and will be asked to sync their device at least once every 7 days. They will be encouraged to look at the device app on their smart phone at least once daily.~After 1 week of obtaining baseline data, subjects will be encouraged to try to obtain a PAI score of at least 30 initially. Once they obtain a score of 30 consistently, they will be encouraged to increase the score toward 50. If they consistently obtain 50, they can increase their goal sequentially toward a maximum goal of 100. The duration of the study will be 12 weeks.
Study NCT01807078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: 10 mg p.d. of ezetimibe
Study NCT01386320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided ankle block
Description: Under ultrasound guidance, block of the tibial nerve, superficial and deep branches of the common peroneal nerve and saphenous nerves will be carried out using 12 mls 0.5% levobupivacaine and 12 mls 0.75% levobupivacaine.
Study NCT01386320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial forefoot block
Description: Using peripheral nerve stimulator guidance, the tibial and common peroneal nerves will be blocked ( plus the saphenous nerve ), using a total of 12 mls 0.75% levobupivacaine and 12 mls 0.5% levobupivacaine.
Study NCT00000249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40% N2O
Description: 40% inhaled N2O
Study NCT01383824 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Silent™ Hip
Description: A short cementless, femoral component for use in total hip arthroplasty
Study NCT02998099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: A single dose of IV rivipansel over 20 minutes.
Study NCT05714228 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical Mitral Valve Repair
Description: Mitral valve is repaired using open surgical approach
Study NCT05714228 — intervention group
Intervention type: PROCEDURE
Intervention: Transcatheter Mitral Valve Repair
Description: Mitral valve is repaired using Mitraclip transcatheter device
Study NCT00510562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cranial osteopathic manipulation
Description: This treatment is performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
Study NCT00510562 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham/Placebo
Description: A laying on of hands with no treatment being performed.
Study NCT03148782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OST Intervention for participants with Organizational skill difficulties
Description: Will undergo two magnetic resonance imaging (MRI) sessions: one within 2 weeks prior to OST treatment and one within 2 weeks of completion of the OST treatment.
Study NCT01197105 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Use of natural product (Schinus terebinthifolius)
Description: Mouthwash (0,3125% of schinus terebinthifolius) 10mL per day during 14 days.
Study NCT03915600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quinoa and Flaxseed
Description: personalized diet added with quinoa and flaxseed
Study NCT02719665 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SPM Emulsion, Dose-modality
Description: Phase 1a Dose-Finding oral SPM administration of increasing dose (15ml, 30ml, and 60ml) by the following schedule:~Days 1 to 5: 15 ml; Days 6 to 14: Washout, no SPM administration; Days 15 to 19: 30 ml; Days 20-28: Washout, no SPM administration; Days 29-33: 60 ml
Study NCT02719665 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SPM Softgel, Dose-Modality
Description: Phase 1b Dose-Finding oral softtel SPM administration of two different doses (2 softgel vs 4 softgel) Days 0 to 5: 2 SPM softgel; Days 6 to 21: Washout, no SPM administration; Days 22 to 26: 4 SPM softgel; Days 27-42: Washout, no SPM administration
Study NCT02719665 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Softgel
Description: Days 43-47: 4 Placebo softgel; Day 48-64 Washout
Study NCT01724463 — intervention group
Intervention type: OTHER
Intervention: Severe Sepsis Management Bundle
Description: Management Bundle includes:~1. Securing Intravenous Access~2. Obtaining Blood Culture~3. Antibiotic Administration~4. Goal Directed Fluid Bolus Therapy~5. Oxygen Administration~6. Measuring Serum Lactate Levels
Study NCT03045458 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tissue level dental implant
Description: After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 tissue-level implants 12 mm in length and 4.8 mm in diameter were inserted in Group I. Cover screw was removed and replaced with healing abutments.
Study NCT03045458 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone level dental implant
Description: After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 bone-level dental implants 12 mm in length and 4.8 mm in diameter were inserted inGroup II. Three months later, second-stage surgery was performed and implant exposed into the oral cavity. Cover screw was removed and replaced with healing abutments. Three months waited for second surgery in bone level implants.
Study NCT02959879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX neoadjuvant chemotherapy
Description: 4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient
Study NCT02959879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX neoadjuvant chemotherapy
Description: 4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient
Study NCT02959879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: curative surgery for resectable pancreatic duct adenocarcinoma
Description: curative surgery for resectable pancreatic duct adenocarcinoma
Study NCT01060345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: three 200mg capsules (600mg total dose of the study drug) with food (within one hour of eating a substantial meal) daily for a minimum of 4 weeks, or until the day before surgery
Study NCT02712814 — intervention group
Intervention type: DRUG
Intervention: Topical hormonal cream (estrogen)
Description: Patients will be instructed to stop hormonal contraception and to apply 0.1 ml topical cream containing 0.1% of estriol to the vestibule, once daily for 3 months
Study NCT02712814 — intervention group
Intervention type: PROCEDURE
Intervention: Pelvic floor physical therapy
Description: PF physical therapy once weekly for 3 months
Study NCT02712814 — intervention group
Intervention type: PROCEDURE
Intervention: Low Level Laser therapy
Description: non-thermal laser irradiation (low levels of red and near infrared light) is applied directly to the vestibule
Study NCT03597217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: 3, 10, 50 mg
Study NCT03597217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: 50 mg multiple dose
Study NCT03597217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04016740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Intraoperative bilateral PIFB block with 20 mL of 0.25% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision
Study NCT04016740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intraoperative infusion
Study NCT04016740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Intraoperative infusion
Study NCT04016740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intraoperative infusion
Study NCT04016740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Intraoperative intermittent bolus
Study NCT04016740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Intraoperative infusion
Study NCT04016740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Intraoperative inhaled as needed
Study NCT04016740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Post-operative infusion
Study NCT02728726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
Study NCT02728726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
Study NCT04909411 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: OPHTHALMOLOGICAL ASSESSMENT
Description: assessment of eye mobility (search for heterophoria or strabismus), visual acuity, visual fields, external structures and funduscopic examination
Study NCT04909411 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NEUROPSYCHOLOGICAL ASSESSMENT
Description: completion of WISC-5, Vineland Adaptive Behavior Scale II and Strengths and Difficulties Questionnaire
Study NCT03556280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaSense Stimulation System (Active Settings)
Description: Proprietary auditory and visual sensory stimulation device.
Study NCT03556280 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GammaSense Stimulation System (Sham Settings)
Description: Proprietary auditory and visual sensory stimulation device.
Study NCT03380988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute test meal with fiber-enriched buckwheat pasta
Description: Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
Study NCT03380988 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute test meal with corn pasta
Description: Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
Study NCT02559960 — intervention group
Intervention type: DRUG
Intervention: Breviscapine Powder-Injection
Description: Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
Study NCT04189588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine HCl 10 mg/mL
Description: Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
Study NCT04189588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine 50 mg/mL
Description: Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
Study NCT01807078 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceuticals
Description: 1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
Study NCT04189588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-CD20 such as Rituximab or Paclitaxel
Description: Compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan® (Rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment. Re-treatment is defined as re-treatment with Rituxan® (Rituximab) or Paclitaxel after 6 months in patients with persistent infusion reactions while on maintenance or re-treatment.
Study NCT03944005 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia + ACB continious catheter + iPACK + Sham LIA
Description: ACB - On identification of adductor canal,10ml ropivacaine 0.5% with 1:400,000 epinephrine will be injected to surround the femoral artery.Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr 0.2% ropivacaine will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of femoral condyle and popliteal artery, 20ml ropivacaine 0.5% with 1:400,000 epinephrine will be infiltrated in muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients in Group 1 will receive local infiltration 100ml of normal saline around the knee capsule of 100ml of normal saline by the surgeons as a Sham injection.
Study NCT03944005 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Spinal Anesthesia + LIA + Sham Blocks
Description: ACB - On identification of adductor canal, 10ml of saline as a sham solution will be injected to surround the femoral artery. Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr of saline will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of the femoral condyle and popliteal artery, 20ml of saline will be infiltrated in the muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following the nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine injected at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients will receive local infiltration by the attending surgeon intraoperatively with 300mg of ropivacaine (100ml of 0.3% ropivacaine),30 mg of ketorolac, and 10mg of morphine around the knee capsule.
Study NCT03592992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinal Hydromorphone
Description: 75 mcg of hydromorphone will be prepared in a non-identifiable syringe by central hospital pharmacy. The resulting solution will then be added to the spinal anesthetic mixture(fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
Study NCT03592992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Morphine
Description: 150 mcg of morphine will be prepared in a non-identifiable syringe by central hospital pharmacy.The resulting solution will be added to the spinal anesthetic mixture (fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
Study NCT01795339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293
Description: Oral solution
Study NCT01795339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution
Study NCT01496859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement and use of Baska mask
Description: use of a supraglottic airway device as a standard part of a general anaesthetic
Study NCT03932383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom CPAP mask
Description: Modified CPAP mask based on 3D image capture
Study NCT00271570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab (Remicade)
Description: Remicade was 5 mg/kg IV (single dose)
Study NCT00271570 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG)
Description: 2nd dose of IVIG (2g/kg)
Study NCT03529422 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Durvalumab
Description: Durvalumab 1500mg IV every 3 weeks for 6 cycles
Study NCT03529422 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity Modulated Radiotherapy Treatments
Description: Total dose will be 60 Gray (Gy) at 2Gy per fractions for 30 fractions delivered Monday through Friday for 6 weeks
Study NCT01103986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational/health literacy education (Test group)
Description: Attend a 1-hour class to learn how to use the book What to Do When Your Child Gets Sick.
Study NCT03627988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients with invasive breast cancer will receive:
Description: * Mastectomy with Immediate prosthetic breast reconstruction~* Adjuvant therapy by TomoTherapy (radiation therapy alone or preceded by chemotherapy).